European Commission approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Marketing | Pharmaceuticals | Small Cell Lung Cancer